Urinary tract infections caused by extended-spectrum betalactamase- producing bacteria in children: A matched casecontrol study

Turkish Journal of Pediatrics

Volumn 55, Issue 6, 2013, Pages 571-574

  Dotis, John ^a   Printza, Nikoleta ^a   Marneri, Alexandra ^a   Gidaris, Dimos ^a   Papachristou, Fotios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Clinical characteristics; Extended spectrum beta lactamase (ESBL); Risk factors; Urinary tract infection

Indexed keywords

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; INFANT; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TURKEY; URINARY TRACT INFECTIONS;

EID: 84893222837     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bitsori M, Maraki S, Kalmanti M, Galanakis E. Resistance against broad-spectrum beta-lactams among uropathogens in children. Pediatr Nephrol 2009; 24: 2381-2386.
2. Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol 2011; 65: 455-478.
3. Ilić T, Gračan S, Arapović A, Capkun V, Subat-Dežulović M, Saraga M. Changes in bacterial resistance patterns in children with urinary tract infections on antimicrobial prophylaxis at University Hospital in Split. Med Sci Monit 2011; 17: CR355-361.
4. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011; 70: 507-511.
5. Pitout JD, Laupland KB. Extended-spectrum betalactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-166.
6. Beetz R, Westenfelder M. Antimicrobial therapy of urinary tract infections in children. Int J Antimicrob Agents 2011; 38: S42-50.
7. Catal F, Bavbek N, Bayrak O, et al. Antimicrobial resistance patterns of urinary tract pathogens and rationale for empirical therapy in Turkish children for the years 2000-2006. Int Urol Nephrol 2009; 41: 953-957.
8. Ghorashi Z, Ghorashi S, Soltani-Ahari H, Nezami N. Demographic features and antibiotic resistance among children hospitalized for urinary tract infection in northwest Iran. Infect Drug Resist 2011; 4: 171-176.
9. Özçakar ZB, Yalçinkaya F, Kavaz A, et al. Urinary tract infections owing to ESBL-producing bacteria: microorganisms change-clinical pattern does not. Acta Paediatr 2011; 100: e61-64.
10. Topaloglu R, Er I, Dogan BG, et al. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatr Nephrol 2010; 25: 919-925.
11. Tratselas A, Iosifidis E, Ioannidou M, et al. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J 2011; 30: 707-710.
12. Kizilca O, Siraneci R, Yilmaz A, et al. Risk factors for community-acquired urinary tract infection with ESBL-producing bacteria in children. Pediatr Int 2012; 54: 858-862.
13. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5 and informational supplement M100-S10. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.